Cervical Cancer in India: Turning the Tide with HPV Vaccination

In February 2026, the Government of India announced a landmark public health initiative: the launch of a free, nationwide Human Papillomavirus (HPV) vaccination programme for adolescent girls. This decision marks one of the most significant preventive health interventions in the country’s history, targeting the elimination of cervical cancer - a disease that continues to claim tens of thousands of lives annually in India despite being largely preventable.

Cervical cancer has long been a heavy burden on Indian women. Yet today we stand at a turning point. With a simple vaccine and a bold national programme, we can stop this disease before it starts. This is how India is now making prevention real for millions of girls.

The Heavy Burden and Silent Cause of Cervical Cancer in India

Cervical cancer is the most frequent cancer among women in India and the second most common cancer in women worldwide. India has roughly 365 million women above age 15 who are at risk. Every year about 80,000 new cases are diagnosed and more than 42,000 women lose their lives, one woman every eight minutes. Indian women face a 2.5 % lifetime risk of getting the disease and a 1.4% risk of dying from it. At any given time, about 6.6% of women carry cervical HPV infection, and types 16 and 18 cause nearly 77% of the cancers here. Warts are seen in 2–25% of people visiting sexually transmitted disease clinics, though community-wide numbers are not fully known.

HPV is a small, non-enveloped DNA virus from the Papillomaviridae family. More than 100 types exist; 15-20 are oncogenic (cancer-causing). The virus spreads through intimate skin-to-skin contact and usually infects the basal epithelium. Most infections are silent and clear naturally within months, but when high-risk types persist for 15-20 years they can turn normal cells into precancerous lesions (CIN-1, CIN-2, CIN-3) and finally invasive cancer. Low-risk types 6 and 11 cause most genital warts. Other cofactors that help the virus do harm include long-term use of hormonal contraceptives, high number of pregnancies, early sexual activity, multiple partners, smoking, HIV co-infection, low socioeconomic status, poor hygiene and diets low in antioxidants. Genetic and immune factors also play a role.

Without action the future looks heavy. The National Cancer Registry Programme, run by the Indian Council of Medical Research, tracks cases through selected urban and rural registries and shows cervical cancer striking women in their most productive years, with a median age of 38. In developing countries like India, late detection and limited screening make the problem worse.

Pap smears help when women attend regularly, but many do not because of cost, distance or lack of awareness. Barrier methods give only partial protection, and abstinence or lifelong monogamy is not practical for everyone. That is why experts have always said prevention must start earlier.

The Breakthrough Science of HPV Vaccines and Their Protection

Scientists found a smart way to fight HPV using recombinant DNA technology. They made the L1 major capsid protein in yeast so it self-assembles into empty virus-like particles that look exactly like HPV but contain no genetic material. These harmless shells train the immune system to recognise the real virus and block it before infection takes hold. The vaccines are prophylactic; they prevent new infections but do not treat existing ones.

Two vaccines led the way in India: Gardasil (quadrivalent, covering types 6, 11, 16, 18) made by Merck and Cervarix (bivalent, covering 16 and 18) made by GlaxoSmithKline. Both are given as 0.5 ml intramuscular injections. Gardasil follows a 0-2-6 month schedule and protects against both cervical cancer and genital warts. Cervarix follows 0-1-6 months and focuses on cancer protection. Clinical trials showed 100 % efficacy for Gardasil and 90 % for Cervarix against vaccine-type CIN-2/3 and adenocarcinoma in situ in women who were HPV-negative at the start. Protection lasted at least 4–5 years with no sign of waning, and antibody levels in girls aged 9–15 were actually two to three times higher than in older teens. A single dose has now been shown in global studies to give robust, long-lasting protection for girls 9-20 years old.

The vaccine is very safe. The most common reactions are mild pain at the injection site (83%), swelling or redness (25%) and low-grade fever (4%). No serious vaccine-related events or deaths have been linked to it anywhere. It is not live, so it cannot cause HPV infection. It can be given with other vaccines like hepatitis B or Tdap. It is not recommended during pregnancy, but is safe for breastfeeding women and those who are mildly ill. The Indian Academy of Pediatrics recommends offering the vaccine to all girls who can afford it, ideally before sexual debut, and always paired with continued screening because no vaccine covers every HPV type. Screening should continue for life.

Early concerns about cost, safety and behaviour change have been answered by data. The vaccine does not encourage risky behaviour. Protection is expected to last decades, though longer studies continue. India’s own Cervavac, a quadrivalent vaccine made by the Serum Institute, is already available privately at a lower price and matches Gardasil in immune response. Single-dose studies for Cervavac are ongoing.

India's 2026 National Rollout: From Research to Real Prevention for Every Girl

The 2012 call for affordable, effective prevention has now become reality. In February 2026 the Government of India cleared a free, voluntary nationwide HPV vaccination programme for all 14-year-old girls. A single dose of Gardasil will be given at government health facilities including Ayushman Arogya Mandirs, primary health centres, community health centres, district hospitals and medical colleges. A 90-day mega awareness and vaccination drive will help reach high coverage quickly. Families can register through the U-WIN portal. The vaccine is procured through partnership with Gavi, the Vaccine Alliance, ensuring quality and cold-chain standards.

This programme removes the biggest barrier cost so every girl, whether in a city or remote village, gets the same protection. It directly addresses health inequity and sends a strong message that women’s preventive health is a national priority. The choice of Gardasil for the start uses its well-proven single-dose data, while Cervavac, India’s indigenous vaccine, is ready to join once its own single-dose studies are complete. This approach builds self-reliance and keeps costs low.

The rollout fits perfectly with WHO’s global elimination targets: 90% of girls vaccinated by age 15, 70% screened, and 90% of precancers treated. Countries that achieved high coverage have already seen up to 90% drops in cervical cancer. In India the programme will cover the 1.15 crore girls who turn 14 each year. Vaccination does not replace screening as women will still need regular check-ups later but it will sharply reduce the number of high-risk infections and ease the load on hospitals.

Looking forward, questions remain about duration of protection, possible boosters, vaccination of boys to stop spread and logistics in every corner of the country. Yet the foundation is strong. The 2012 review asked for cheaper vaccines, better awareness and political will. Today we have all three.

When families talk about the vaccine as “cancer prevention”, when schools and health workers spread the message, and when every eligible girl receives her dose, cervical cancer can become a disease of the past. India is showing the world that prevention is possible, affordable and life-changing. The science was ready; now the action has begun. Together we can turn today’s hope into tomorrow’s victory for every daughter.